DOCSLIB.ORG

Benign Pathologies and Variants with 68Ga-Dotatate Uptake in PET/CT Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Benign Pathologies and Variants with 68Ga-Dotatate Uptake in PET/CT Studies Original Benign Pathologies and Variants with 68ga-Dotatate Uptake in PET/CT Studies L. Servente, C. Bianco, V. Gigiret and O. Alonso Centro Uruguayo de Imagenología Molecular, CUDIM, Montevideo, Uruguay Abstract Purpose: To evaluate the physiological, anatomical variants and benign lesions in positron emission computed tomog- raphy (PET/CT) studies with 68Ga-DOTATATE. Materials and methods: We retrospectively reviewed reports of 68Ga-DOTATATE PET/CT scans and selected those that contained words in the report related to anatomical, physiological variants and benign tumors. The degree of 68Ga-DOTATATE uptake was qualitatively and quantitatively evaluated by measuring the standardized uptake max value (SUVmax value). The anatomical location, SUVmax value and morphological computed tomography (CT) image findings were recorded. All cases had a clinical and imaging follow-up. Results: From a total of 772 PET/CT reports, we obtained 28 patients with 33 benign variants or tumors, 14 females and 14 males with a median age of 63 years. Uptake patterns were classified into four groups: anatomic and physi- ological variants (n = 15), dependent on osteoblastic activity (n=4), dependent on inflammatory activity (n=10) and non-neuroendocrine benign tumors (n=4). Discussion: Somatostatin receptors are overexpressed not only in the neuroendocrine system but also in other tissues. Physiological, anatomical variants and benign tumors expressing these receptors may be misleading. Conclusion: Physiological variants and benign lesions (tumor and inflammatory lesions) can accumulate 68Ga-DOT- ATATE since their tissues can express somatostatin receptors. The semiological analysis of the tomographic component of this hybrid imaging method enhances the diagnostic efficacy, optimizing PET/CT study performance. © 2017 Sociedad Argentina de Radiología. Published by Elsevier Spain, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Keywords: 68-Gallium DOTATATE; Positron emission tomography/computed tomography; Somatostatin receptors; Hy- brid imaging Introduction The biodistribution of this tracer shows the highest uptake in the spleen, followed by adrenal glands, the pituitary gland Positron emission tomography combined with computer to- and the kidney. In decreasing order of uptake intensity, these mography (PET/CT) using 68 Gallium (68Ga)-DOTATATE, a are followed by the liver, salivary glands and the thyroid6,7. radioactively labeled somatostatin (SST) analog, is a first-line The uptake in the stomach, small and large bowel is variable hybrid imaging method for the evaluation of patients with because of neuroendocrine cell hyperplasia. In the pancreas, well-differentiated neuroendocrine tumors (NET) for local- the presence of a larger number of cells expressing soma- izing the primary tumor, staging-restaging tumors and se- tostatin receptors has been reported, mainly in the pancreatic lecting patients for radionuclide therapy1-4. This method has head and in the uncinate process6,8,9. also been used in the imaging of granulomatous and auto- As there is an overlap in uptake intensity between benign and immune conditions as well as of other non-neuroendocrine malignant lesions, it is essential to know the anatomic, physi- tumors, although in these cases it cannot be considered as ologic variants and benign entities that most frequently occur the first-choice functional imaging modality3,5. as findings unrelated to the underlying tumor. Somatostatin receptors are distributed in the whole body. The aim of this study is to consider the physiologic, anatomic Normal tissues and benign diseases (benign tumors or in- variants and benign lesions in PET/CT scans with 68Ga-DOT- flammatory conditions) can also express these receptors and ATATE that may constitute potential sources of diagnostic error. therefore can also show increased uptake of this tracer. 184 Rev. Argent. Radiol. 2017;81(3): 184-191 L. Servente et al. Materials and methods droma, inflammatory, uncinate, accessory spleen, splenosis, prostatitis, fracture, accessory, reactive, dysplasia, fibrous. Patients gave their written informed consent authorizing the use of their scans and clinical data for scientific purposes; Image acquisition data were anonymized. Because of its retrospective design, 68Ga-DOTATATE was injected at a dose of 2.5 MBq/kg of the study was not submitted to the Ethics Committee. weight. At 30 minutes post-injection, 3D images were ac- quired by PET/CT with and without tomography attenuation Selection of scans correction on 16- and 64-slice General Electric (GE) hybrid We retrospectively reviewed a total of 772 reports of 68Ga- scanners (Discovery STE and 690 Discovery, respectively). DOTATATE PET/TC scans performed to 639 patients between Images were recorded from the skull to the middle third of June 2011 and June 2016. A search was performed in the site the femoral shaft for 120 seconds/bed for the STE Discovery database for the following keywords mentioned in reports: scanner and for 90 seconds/bed for the 690 Discovery scan- hemangioma, angioma, schwannoma, meningioma, enchon- ner. Computed tomography (CT) was performed with 80-180 Table 1: Description of indication, gender, age, SUVmax and findings. Patient # FINDING SUV 1 SUV 2,3 AGE GENDER INDICATION 1 Paget 6.4 79 M Prostate cancer 2 Fracture 6.7 34 M Oncogenic osteomalacia 3 Echondroma 3.8 53 F NETUP 4 Accessory spleen 18.8 65 F Gastrointestinal NET 5 Accessory spleen 14 60 M NETUP 6 Accessory spleen 17.4 13 M Gastrointestinal NET 7 Splenosis 21 70 F Pancreatic NET 8 Splenosis 10 56 F Pancreatic NET 9 Duodenum variant 10 44 M Adrenal carcinoma 10 Pancreas variant 12.5 21 M Multicenter ganglioneuroma, MEN syndrome 11 Pancreas variant 9.6 70 F Gastrointestinal NET 12 Pancreas variant/accessory spleen 8.3 13.1 56 F Insulinoma 13 Uterine uptake 4.4 63 F Gastrointestinal NET 14 Uterine uptake 5.7 44 F NETUP 15 Uterine uptake 4.6 76 F Pancreatic NET 16 Uterine uptake/ degenerative disc disease 9.1 6.7 54 F NETUP 17 Bone hemangioma 7.9 51 M Gastrointestinal NET 18 Bone hemangioma 6.6 57 M Prostate cancer 19 Hemangioma/fracture/inflammatory 3.9 4.3/4.1 74 F Medullary thyroid carcinoma 20 Lymph node chronic inflammation 5.5 41 M Mediastinal adenopathies 21 Lymph node chronic inflammation 3.7 24 M Mediastinal adenopathies 22 Postoperative chronic inflammation 7.1 66 M Gastrointestinal NET 23 Degenerative disc disease/accessory spleen 6.1 22 65 F Invasive thymoma / insulinoma 24 Prostatitis 5.9 63 M Gastrointestinal NET 25 Cerebral falx meningioma 5.1 69 F Breast cancer, dural lesion 26 CPA meningioma 3.1 64 M NETUP 27 Cerebral falx meningioma 5.2 72 M Pulmonary NET 28 Left C4 schwannoma 8.8 69 F Gastrointestinal NET Patient # 1 to 3: findings dependent on osteoblastic activity. Patients # 4 to 16: anatomic and physiological variants. Patients # 17 to 24: chronic inflammation. Patients # 25 to 28: non-neuroendocrine tumors. Ca: cancer; MEN 1: multiple endocrine neoplasia syndrome 1, NETUP: neuroendocrine tumor of unknown primary, NET: neuroendocrine tumor. Rev. Argent. Radiol. 2017;81(3): 184-191 185 Benign Pathologies and Variants with 68ga-Dotatate Uptake in PET/CT Studies mA, 120 kV (noise index, 20) and 3.75-mm slice thickness, experience in hybrid imaging. pitch 1,375 and table movement 27.5 mm per rotation for Data were recorded on uptake location, SUVmax value, the STE Discovery scanner and 17.5 mm per rotation for the oth- CT morphological image, age, gender, the reason for per- er scanner. Emission data were processed by iterative recon- forming the PET scan, the use of radiological contrast and struction (OSEM). All patients received an oral contrast agent follow-up. An electronic datasheet was prepared. and the intravenous (IV) contrast only when indicated by the Histological confirmatory tests were performed in two pa- imaging specialist. No late phase imaging was performed. tients: CT-guided aspiration in one patient and laparotomy in the other. In all other patients benign findings were con- Evaluation of images firmed by their clinical course and an imaging follow-up (CT, Axial, coronal and sagittal images as well as maximum-in- MRI or PET/CT) between 6 months and 6 years, with an aver- tensity projection (MIP) images were evaluated. The degree age follow-up of 1 year. of 68Ga-DOTATATE uptake was evaluated by a qualitative and quantitative visual analysis, with the latter being done by maximum standardized uptake value (SUVmax) measure- Results ment. Images were analyzed on GE Advantage workstations, versions 4.5 and 4.6. The scans were reviewed jointly by two Out of 772 reports performed during a 5-year period (corre- physicians: a nuclear medicine specialist and a radiology spe- sponding to 639 patients), 101 contained the keywords listed cialist, both certified and with 5 years’ experience in conven- above. Reports in which the keyword was unrelated to the tional nuclear medicine and radiology and at least 2 years’ aim of our study were excluded. Figure 1 Patient # 10. Male, 21 years old. Left adrenal multicentric ganglioneuroma resection. Multiple endocrine neoplasia syndrome. Physiological variant of the uncinate process. (a) MIP PET image shows abdominal focal uptake (arrow), (b) Axial PET image and (c) fused PET/CT image with IV contrast: focal uptake in uncinate process (arrow) SUVmax 12.5. 186 Rev. Argent. Radiol. 2017;81(3): 184-191 L. Servente et al. Figure 2 Patient # 8. Female, 56 years old, caudal pancreatectomy and splenectomy for NET of the pancreatic tail. PET/CT scan for restaging. Splenosis. (a) Axial fused PET/CT image shows focal uptake in splenosis (arrow). SUVmax 10, (B) MIP PET image shows focal uptake (arrow). Figure 3 Patient # 3. Female, 53 years old. Carotid adenopathy resection. Pathology examination reported neuroendocrine metastasis. PET/CT for localization of the primary tumor. Finding: enchondroma. (a) Coronal CT: left femoral intertrochanteric lesion.
Load more

Recommended publications
  • Rare APC Promoter 1B Variants in Gastric Cancer Kindreds Unselected
    PostScript with familial adenomatous polyposis.3 However, the prevalence of APC promoter Gut: first published as 10.1136/gutjnl-2020-321990 on 7 September 2020. Downloaded from variants in molecularly undiagnosed GC kindreds unselected for fundic gland polyp- osis is unknown. To investigate the contribution of APC promoter variants to GC predisposition in families lacking causal germline vari- ants CDH1, which account for 19%–40% of HDGC, we performed multigene sequencing in 259 individuals from 254 families ascertained on the basis of personal and/or family history of GC (table 1). This included 174 individuals meeting Inter- national Gastric Cancer Linkage Consor- tium criteria for HDGC and one meeting criteria for FIGC.4 The majority (76.8%) of individuals had a personal history of GC, with 85.4% diffuse GC and median age of diagnosis of 42 years (range 9–87). Six additional individuals were potential obli- gate carriers for GC predisposition. The APC promoter 1B was analysed by next- Rare APC promoter 1B variants generation sequencing (n=232) or Sanger in gastric cancer kindreds sequencing (n=27) in all index cases. unselected for fundic We identified a pathogenic variant (APC gland polyposis c.-191T>C) in an obligate carrier meeting clinical criteria for HDGC (figure 1). The index case (III-8) was diagnosed with pros- Although multiple demographic, environ- tate cancer at the age of 73, following mental and genetic factors contribute to a diagnosis of GC in two children. IV-2 gastric cancer (GC) risk, familial clustering initially presented with lower abdominal occurs in around 10%–15% of cases.1 pain, distension and ascites at 37 years A strong genetic predisposition under- of age.
    [Show full text]
  • C O N F E R E N C E 7 18 October 2017
    Joint Pathology Center Veterinary Pathology Services WEDNESDAY SLIDE CONFERENCE 2017-2018 C o n f e r e n c e 7 18 October 2017 CASE I: F1753191 (JPC 4101076). veterinarian revealed a regenerative anemia, stress leukogram and hypoproteinemia Signalment: 9-year-old, female intact, Rock characterized by hypoalbuminemia and the Alpine goat, Capra aegagrus hircus, goat was treated with ivermectin. caprine. Bloodwork at CSU revealed hyperglycemia and elevated creatinine, creatine kinase and History: A 9-year-old, female intact Rock aspartate aminotransferase levels. A fecal Alpine goat presented to Colorado State floatation revealed heavy loads of coccidia, University Veterinary Teaching Hospital strongyles and Trichuris spp. During a nine two months prior to necropsy with a three- day hospitalization, the doe was treated with day history of hyporexia and lethargy which intravenous fluids, kaopectate, thiamine, had progressed to lateral recumbency and fenbendazole, sulfadimethoxine, oxy- complete anorexia. The referring tetracycline and multiple blood transfusions. veterinarian had previously diagnosed the After significant improvement of her clinical doe with louse infestation, endoparasites and signs and bloodwork, including partial a heart murmur. Bloodwork by the referring resolution of the dermatitis, the doe was Haired skin goat. The skin was dry, alopecia, and covered with hyperkeratotic crusts and ulcers. (Photo courtesy of: Colorado State University, Microbiology, Immunology, and Pathology Department, College of Veterinary Medicine and Biomedical Sciences, http://csucvmbs.colostate.edu/academics/mip/Pages/default.aspx) 1 discharged. exfoliating epithelial crusts which were often tangled within scant remaining hairs. Two months later, the goat presented with a This lesion most severely affected the skin one month history of progressive scaling and over the epaxials, the ventral abdomen and ulceration over the withers, dew claws, and teats, coronary bands and dew claws.
    [Show full text]
  • Complications of Splenectomy 2020; 4(2): 218-222 Received: 08-02-2020 Dr
    International Journal of Surgery Science 2020; 4(2): 218-222 E-ISSN: 2616-3470 P-ISSN: 2616-3462 © Surgery Science Complications of splenectomy www.surgeryscience.com 2020; 4(2): 218-222 Received: 08-02-2020 Dr. Ketan Vagholkar Accepted: 10-03-2020 Dr. Ketan Vagholkar DOI: https://doi.org/10.33545/surgery.2020.v4.i2d.420 Professor, Department of Surgery. DY Patil University School of Abstract Medicine Navi Mumbai, Spleen is an important organ of the reticuloendothelial system. It plays a crucial role in the immunological Maharashtra, India system of the body. Understanding the consequences and diagnosis of hyposlenic and asplenic states is essential. Splenectomy is performed for a variety of indications ranging from haematological conditions to trauma. Complications of splenectomy include surgical as well as immunological. Overwhelming post splenectomy infection is one of the most dreaded complication with high mortality. The physiological basis of immunological function of the spleen, hyposplenism and complications of splenectomy are presented in this paper. Keywords: Post splenectomy, complications, hyposplenia, OPSI Introduction Spleen is a very important constituent organ of the reticuloendothelial system. The organ is crucial in regulating immune homeostasis through its ability to link innate and adoptive immunity in the process of protecting against infection. Hyposplenism is impairment of splenic function. It is usually acquired and caused by severe haematological and immunological disorders. Asplenia refers to the absence of the spleen which is rarely congenital but predominantly post-surgical (splenectomy). The most important complication of asplenic state is infectious complications [1]. These infections have high mortality. In addition to infectious complications, splenectomy can lead to a series of other complications.
    [Show full text]
  • The Future: Surgical Advances in MEN1 Therapeutic Approaches And
    2410 S M Sadowski et al. Advances in surgical 24:10 T243–T260 Thematic Review management of MEN1 The future: surgical advances in MEN1 therapeutic approaches and management strategies S M Sadowski1, G Cadiot2, E Dansin3, P Goudet4 and F Triponez1 1Thoracic and Endocrine Surgery and Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland 2Gastroenterology and Hepatology, University Hospital of Reims, Reims, France 3 Oncology, Oscar Lambret Cancer Center, University of Lille, Lille, France Correspondence 4 Endocrine Surgery, University Hospital of Dijon, and INSERM, U866, Epidemiology and Clinical Research in Digestive should be addressed Oncology Team, and INSERM, CIC1432, Clinical Epidemiology Unit, University Hospital of Dijon, Clinical Investigation to F Triponez Centre, Clinical Epidemiology/Clinical Trials Unit, Dijon, France Email [email protected] Abstract Multiple endocrine neoplasia type 1 (MEN1) is a hereditary autosomal dominant Key Words disorder associated with numerous neuroendocrine tumors (NETs). Recent advances in f multiple endocrine the management of MEN1 have led to a decrease in mortality due to excess hormones; neoplasia type 1 (MEN1) however, they have also led to an increase in mortality from malignancy, particularly f neuro-endocrine tumors (NET) NETs. The main challenges are to localize these tumors, to select those that need f thymic NET therapy because of the risk of aggressive behavior and to select the appropriate therapy f pancreatico-gastro-intestinal associated with minimal morbidity. This must be applied to a hereditary disease with a NET Endocrine-Related Cancer Endocrine-Related high risk of recurrence. The overall aim of management in MEN1 is to ensure that the f lung NET patient remains disease- and symptom-free for as long as possible and maintains a good quality of life.
    [Show full text]
  • Well-Differentiated Angiosarcoma of Spleen: a Teaching Case Mimicking
    Xu et al. World Journal of Surgical Oncology (2015) 13:300 DOI 10.1186/s12957-015-0716-1 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Well-differentiated angiosarcoma of spleen: a teaching case mimicking hemagioma and cytogenetic analysis with array comparative genomic hybridization Lichen Xu1†, Yimin Zhang1†, Hong Zhao1, Qingxiao Chen2, Weihang Ma1,3* and Lanjuan Li1 Abstract Primary splenic angiosarcoma is extremely rare but aggressive malignant vascular neoplasm. Here, we report a case of vascular tumor in spleen that was initially misinterpreted as hemangioma. Two years after splenectomy, the patient admitted again with aggravated abdomen pain and severe anemia. The magnetic resonance imaging (MRI) scan showed widely metastases. The ensuing biopsy for lesion both in liver and in bone marrow showed the similar pathological findings as that in spleen, which supported the final diagnosis of well-differentiated splenic angiosarcoma with extensive metastases. The patient was dead in 3 months after discharge without chemotherapy. The copy number changes for spleen lesion detected by array comparative genome hybridization showed copy number gain at 11q23.2, 11q24.3, 12q24.33, 13q34, copy number loss at 1q24.2-q31.3, 1q41-q42.2, 1 q42.3-q43, 2q36.3-q37.3, 2q37.7, 3q13.33-q26.2, 3q28 - q29, 9p11.2, 13q11, 15q11, homozygous copy loss at 8p11.22, 22q11.23. Less than 200 cases of splenic angiosarcoma have been published in literature of English. To the best of our knowledge, this is the first time analyzed cytogenetic alteration in a well-differentiated primary splenic angiosarcoma. Keywords: Angiosarcoma, Well-differentiation, Splenectomy, Array comparative genomic hybridization, Copy number change Background cytogenetic changes to this subgroup of angiosarcoma Primary splenic angiosarcoma (PSA) is a rare malignant has been published.
    [Show full text]
  • Carcinoid Tumour of the Thymus Gland: Report of a Case
    Thorax: first published as 10.1136/thx.30.4.470 on 1 August 1975. Downloaded from Thorax (1975), 30, 470. Carcinoid tumour of the thymus gland: report of a case J. PRESTON HUGHES', NELSON ANCALMO', GEORGE L. LEONARD2, and JOHN L. OCHSNER' Departments of Surgery1 and Pathology2, Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA Preston Hughes, J., Ancalmo, N., Leonard, G. L., and Ochsner, J. L. (1975). Thorax, 30, 470-475. Carcinoid tumour of the thymus gland: report of a case. Carcinoid of the thymus is a rare problem. A case is reported to add to only 16 previously reported. None of these 17 patients had the carcinoid syndrome. Complete surgical excision, if possible, is the treatment of choice. A primary carcinoid tumour of the thymus is and a large anterior mediastinal tumour was re- very rare. Rosai and Higa (1972) collected eight sected through a median sternotomy. The involved cases and found only eight additional cases in the pericardium and left phrenic nerve were excised literature. A patient with this unusual lesion was with the large discrete mass. Grossly, the tumour treated at Ochsner Foundation Hospital and the measured 12X9X7 cm and weighed 290 g (Fig. case report is presented, emphasizing the import- 3). It was well-circumscribed, oval, and apparentlycopyright. ance of complete excision. encapsulated; the cut surface was homogeneous, smooth, firm, grey-white, and fleshy. Micro- CASE REPORT scopically the tumour was composed of small, A 32-year-old white man visited the emergency closely packed cells with nuclei that were uniform in http://thorax.bmj.com/ room on 16 February 1974, because of severe size and shape with few mitotic figures (Figs upper back and chest pain.
    [Show full text]
  • Human Autoimmunity and Associated Diseases
    Human Autoimmunity and Associated Diseases Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün This book first published 2021 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2021 by Kenan Demir and Selim Görgün and contributors All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-5275-6910-1 ISBN (13): 978-1-5275-6910-2 TABLE OF CONTENTS Preface ...................................................................................................... viii Chapter One ................................................................................................. 1 Introduction to the Immune System Kemal Bilgin Chapter Two .............................................................................................. 10 Immune System Embryology Rümeysa Göç Chapter Three ............................................................................................. 18 Immune System Histology Filiz Yılmaz Chapter Four .............................................................................................. 36 Tolerance Mechanisms and Autoimmunity
    [Show full text]
  • Accessory Spleen ORIGINAL RESEARCH ARTICLE
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 10 Ver.III (Oct. 2015), PP 01-03 www.iosrjournals.org Accessory spleen ORIGINAL RESEARCH ARTICLE V. Durgesh*1, CH. Roja Rani2 1Associate Professor Department of Anatomy Faculty of Medicine Maharajah Institute of Medical Sciences Nellimarla Vizianagaram district Andhra Pradesh 2.Assistant Professor Mims, Nellimarla Vizianagaram Distrct Andhrapradesh Abstract: Accessory spleen is a congenital failure of fusion of splenicules usually found close to the splenic hilum or in the greater omentum or tail of the pancreas. Though mostly asymptomatic, these could confuse the diagnosis of certain tumors and also be the cause of relapse post splenectomy. The aim of this article is to present a case of accessory spleen found during the dissection and discuss the various diagnostic procedures, clinical implications and focus on splenosis. Key words: accessory spleen, splenosis, dorsal mesogastrium I. Introduction During the fifth week of intrauterine life, mesenchymal condensations called ‘splenicules” start to appear in the left leaf of dorsal mesogastrium which eventually fuse to form the spleen. Any failure of this fusion results in small splenic tissues developing separately and resulting in accessory spleens. They are relatively common, with an autopsy study involving 3000 patients identifying 364 accessory spleens, of which 61 were found in the pancreatic tail. The pancreatic tail and the splenic hilum are the most common sites though accessory spleens can be found anywhere along the line of dorsal mesogastrium and close to the urogenital ridge such as the stomach, jejunum, mesentery as well as the ovaries, spermatic cord,scrotum1and testis.
    [Show full text]
  • Immunohistochemical Differential Diagnosis Between Thymic Carcinoma and Type B3 Thymoma: Diagnostic Utility of Hypoxic Marker, GLUT-1, in Thymic Epithelial Neoplasms
    Modern Pathology (2009) 22, 1341–1350 & 2009 USCAP, Inc. All rights reserved 0893-3952/09 $32.00 1341 Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms Masakazu Kojika1,2, Genichiro Ishii1, Junji Yoshida2, Mituyo Nishimura2, Tomoyuki Hishida2, Shu-ji Ota1, Yukinori Murata1, Kanji Nagai2 and Atsushi Ochiai1 1Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan and 2Thoracic Surgery Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%.
    [Show full text]
  • Slug Overexpression Is Associated with Poor Prognosis in Thymoma Patients
    306 ONCOLOGY LETTERS 11: 306-310, 2016 Slug overexpression is associated with poor prognosis in thymoma patients TIANQIANG ZHANG, XU CHEN, XIUMEI CHU, YI SHEN, WENJIE JIAO, YUCHENG WEI, TONG QIU, GUANZHONG YAN, XIAOFEI WANG and LINHAO XU Department of Thoracic Surgery, The Affiliated Hospital, Qingdao University, Qingdao, Shandong 266003, P.R. China Received November 4, 2014; Accepted May 22, 2015 DOI: 10.3892/ol.2015.3851 Abstract. Slug, a member of the Snail family of transcriptional previously been regarded as a benign disease, but more recent factors, is a newly identified suppressive transcriptional factor evidence indicated that it is a potentially malignant tumor of E‑cadherin. The present study investigated the expression requiring prolonged follow‑up (4). However, biomarkers for pattern of Slug in thymomas to evaluate its clinical significance. thymoma diagnosis and prognosis have not yet been estab- Immunohistochemistry was used to investigate the expression lished. pattern of the Slug protein in archived tissue sections from Slug is a member of the Snail family of zinc‑finger tran- 100 thymoma and 60 histologically normal thymus tissue scription factors and was first identified in the neural crest and samples. The associations between Slug expression and developing mesoderm of chicken embryos (5). Slug induces the clinicopathological factors, such as prognosis, were analyzed. downregulation of E-cadherin, an adhesion molecule, leading Positive expression of Slug was detected in a greater propor- to the breakdown of cell-cell adhesions and the acquisition of tion of thymoma samples [51/100 (51%) patients, P<0.001] invasive growth properties in cancer cells (6). These changes compared with normal thymus tissues [9/60 (15%) cases].
    [Show full text]
  • Cholangiocarcinoma Associated With
    Schmidt et al. Journal of Medical Case Reports (2016) 10:200 DOI 10.1186/s13256-016-0989-1 CASE REPORT Open Access Cholangiocarcinoma associated with limbic encephalitis and early cerebral abnormalities detected by 2-deoxy-2- [fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission tomography: a case report Sergio L. Schmidt1,2,3*, Juliana J. Schmidt1,2, Julio C. Tolentino2, Carlos G. Ferreira4,5, Sergio A. de Almeida6, Regina P. Alvarenga2, Eunice N. Simoes2, Guilherme J. Schmidt2, Nathalie H. S. Canedo7 and Leila Chimelli7 Abstract Background: Limbic encephalitis was originally described as a rare clinical neuropathological entity involving seizures and neuropsychological disturbances. In this report, we describe cerebral patterns visualized by positron emission tomography in a patient with limbic encephalitis and cholangiocarcinoma. To our knowledge, there is no other description in the literature of cerebral positron emission tomography findings in the setting of limbic encephalitis and subsequent diagnosis of cholangiocarcinoma. Case presentation: We describe a case of a 77-year-old Caucasian man who exhibited persistent cognitive changes 2 years before his death. A cerebral scan obtained at that time by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission tomography showed low radiotracer uptake in the frontal and temporal lobes. Cerebrospinal fluid analysis indicated the presence of voltage-gated potassium channel antibodies. Three months before the patient’s death, a lymph node biopsy indicated a cholangiocarcinoma, and a new cerebral scan obtained by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography- positron emission tomography showed an increment in the severity of metabolic deficit in the frontal and parietal lobes, as well as hypometabolism involving the temporal lobes.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]